ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections.
0 ratings in the last 12 months
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.